










Clinical and laboratory differences in characteristics of patients with early-onset and late-onset systemic lupus erythematosus: a single-center retrospective study

Radosław Dziejczak^{1,2} , Lech Zaręba³ , Andżelika Siwiec-Koźlik² , Magdalena Spałkowska⁴ ,
Agnieszka Padjas⁵ , Stanisława Bazan-Socha⁵ , Mariusz Korkosz^{2,6} ,
Joanna Kosatka-Węgiel^{2,6}  

¹Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Krakow, Poland

²Clinical Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Poland

³Faculty of Exact and Technical Science, Institute of Computer Science, University of Rzeszow, Poland

⁴Department of Dermatology, Jagiellonian University Medical College, Krakow, Poland

⁵Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

⁶Department of Rheumatology and Immunology, Jagiellonian University Medical College, Krakow, Poland

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with clinical and laboratory characteristics influenced by the age of onset. Despite its significance, data on late-onset SLE (Lo-SLE) compared to early-onset SLE (Eo-SLE) remain limited, particularly in the Polish population. We investigated differences between Lo-SLE and Eo-SLE patients (using 50 years as a cutoff), aiming to improve the diagnosis and management of SLE patients across different age groups.

Material and methods: We conducted a retrospective analysis of medical records from all SLE patients treated at the University Hospital in Krakow, Poland, from 2012 to 2022. All included patients met the 2019 European Alliance of Associations for Rheumatology and American College of Rheumatology classification criteria for SLE.

Results: We analyzed 710 patients with Eo-SLE (77.9%) and 201 patients with Lo-SLE (22.1%). Compared to the Eo-SLE group, the Lo-SLE group exhibited shorter disease duration ($p < 0.001$), a higher mortality rate ($p < 0.001$), and distinct clinical features: less involvement of the central nervous system ($n = 5$, 2.5% vs. $n = 51$, 7.23%, $p = 0.014$) and kidney ($n = 49$, 24.38% vs. $n = 294$, 41.41%, $p < 0.001$), more frequent interstitial lung disease ($n = 19$, 9.45% vs. $n = 27$, 3.84%, $p = 0.001$), and a higher prevalence of cardiovascular, metabolic, and neoplastic comorbidities ($p < 0.05$, for all). Autoantibody profiles also differed: in Lo-SLE compared to Eo-SLE patients, anti-SSB were more common, while anti-histone, anti-nucleosome, anti-RNP, and anti-dsDNA antibodies were less prevalent. Late-onset SLE patients received immunosuppressive treatment less often than Eo-SLE patients.

Conclusions: Late-onset SLE patients exhibit different disease manifestations but with a higher prevalence of interstitial lung disease, internal medicine comorbidities, malignancies, and cardiovascular events compared to Eo-SLE. Our findings highlight the need for tailored management strategies in elderly SLE patients.

Key words: early-onset systemic lupus erythematosus, late-onset systemic lupus erythematosus, systemic lupus erythematosus, interstitial lung disease, comorbidities.

Address for correspondence

Joanna Kosatka-Węgiel, Department of Rheumatology and Immunology, Jagiellonian University Medical College, 2 Jakubowskiego St., 30-688 Krakow, Poland, e-mail: joanna.kosalka@uj.edu.pl

Submitted: 25.03.2025; Accepted: 11.07.2025; Published online: 23.03.2026

Introduction

Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disease driven by dysregulation of the immune system, particularly through the abnormal activation of T and B lymphocytes [1]. That leads to the production of autoantibodies and immune complexes that trigger inflammation, resulting in tissue and organ damage. The disease predominantly affects women of childbearing age [2]. Despite advancements in treatment, mortality rates in SLE remain notably high, particularly among older patients, with infections and cardiovascular complications being the primary causes of death [3, 4]. Thus, SLE diagnosed in patients older than 50 (late-onset SLE – Lo-SLE) presents distinct clinical challenges, including diagnostic delays, a higher multimorbidity burden, and the need for tailored therapeutic strategies to minimize long-term complications associated with ageing [5].

The pathogenesis of Lo-SLE, including sex hormone levels, differs from that of early-onset SLE (Eo-SLE, diagnosed before age 50) [4, 6, 7]. Late-onset SLE represents about 2–20% of all SLE cases, with a lower female-to-male ratio than Eo-SLE [4, 7]. Patients with Lo-SLE typically experience a more insidious disease progression, encounter the classic symptoms less frequently, and exhibit lower disease activity than Eo-SLE [8]. Autoantibody profiles also differ regarding the age of SLE onset [4]. For example, Lo-SLE exhibits lower frequencies of anti-double-stranded DNA (dsDNA), anti-nucleosome, anti-Smith (Sm), and anti-ribonucleoprotein (RNP) antibodies compared to Eo-SLE [7]. Inversely, rheumatoid factor is found more frequently in Lo-SLE [4]. Moreover, older patients often had medical comorbidities, and their initial SLE signs and symptoms could be misinterpreted. Consequently, the disease onset might not be diagnosed promptly [4, 9]. The course of Lo-SLE presents with less organ involvement, but certain manifestations such as arthritis, pleuritis, pericarditis, myositis, pulmonary fibrosis, and associated Sjögren's disease (SjD) have been reported more frequently [4, 7]. Additionally, Lo-SLE patients may have a higher incidence of thromboembolism with positive laboratory test results for antiphospholipid syndrome (APS) [7]. However, findings on these manifestations remain inconsistent across studies [4, 9]. In some of them, organ damage appears to be more prevalent in the Lo-SLE group, which could be related to iatrogenic factors such as osteoporosis and age-related health issues. Therefore, the question arises about the perception of Lo-SLE as a milder SLE form [7].

In the Polish population, there is still a lack of comprehensive studies exploring clinical and laboratory differences between Lo-SLE and Eo-SLE patients [9]. Therefore, we decided to analyze the clinical and labo-

ratory characteristics of Lo-SLE in a large cohort of SLE patients treated at our hospital and compare them to those of Eo-SLE. By identifying distinct patterns and potential risk factors, we seek to contribute to improved personalized management for SLE patients across different age groups.

Material and methods

Study population

A retrospective analysis was conducted using medical records of adult patients diagnosed with SLE (using disease code ICD10: M32) at the University Hospital in Krakow, Poland, from 2012 to 2022. All included patients fulfilled the classification criteria established by the 2019 European Alliance of Associations for Rheumatology (EULAR) and American College of Rheumatology (ACR) guidelines [10].

Our previous publication described the methods in detail [11]. Data collection included comprehensive demographic information (e.g., age, sex, and family history of autoimmune diseases), clinical manifestations, and laboratory findings. Specific data points included the timing of symptom onset and diagnosis, disease duration, systemic comorbidities, miscarriage history (for female patients), therapeutic interventions, and, where applicable, the cause and age at death. "Age at diagnosis" was defined as the age at the time of SLE diagnosis by a physician, according to the SLE classification criteria. "Age at symptoms" was defined as the age at which the first symptoms related to lupus occurred. Clinical manifestations assessed encompassed skin involvement, joint symptoms, serositis, hematological abnormalities, organ-specific conditions (affecting kidneys, liver, nervous system, or respiratory system), Raynaud's phenomenon (RP), and lymphadenopathy. Neuropsychiatric lupus was assessed using the 1999 ACR criteria [12]. For detailed definitions, see our previous publication [11].

Patients were then divided into 2 groups based on their age at the time of diagnosis: those with Lo-SLE, defined as diagnosis at or after the age of 50, and those with Eo-SLE, diagnosed before the age of 50.

Laboratory analysis

Laboratory assessments were performed using standard methods, including complete blood cell count analyses, lipid profile, creatinine level (with glomerular filtration rate estimated by the MDRD formula), 24-hour urine protein excretion, and urine sediment evaluation. Antinuclear antibodies (ANA) were detected using indirect immunofluorescence on HEp-2 cell slides. Further identification of specific antibodies was conducted using enzyme-linked immunosorbent assay (ELISA) or

Table I. Demographic characteristics of patients with early-onset and late-onset systemic lupus erythematosus

Characteristic	Patients with Eo-SLE (n = 710)	Patients with Lo-SLE (n = 201)	p
Female sex [n (%)]	637 (89.72)	175 (87.07)	0.29
Female to male ratio, n	8.72	6.73	< 0.001
Current age [years]	45 (36–54)	67 (62–72)	< 0.001
Age at SLE onset [years]	30 (23–39)	58 (54–65)	< 0.001
Age at first SLE symptoms [years]	28 (21–37)	56 (51–63)	< 0.001
Time from first SLE symptoms to diagnosis [years]	0 (0–2)	1 (0–4)	< 0.001
SLE duration [years]	15 (9–22)	10 (5–16)	< 0.001
Death [n (%)]	20 (3.03)	19 (11.38)	< 0.001

Categorical variables are presented as numbers with percentages, and continuous variables are presented as medians with Q1–Q3 ranges. Statistically significant differences are bolded.

Eo-SLE – early-onset systemic lupus erythematosus, Lo-SLE – late-onset systemic lupus erythematosus, SLE – systemic lupus erythematosus.

line-blot immunoassay, including the evaluation of anti-dsDNA antibody presence. Anti-dsDNA antibodies were additionally assessed on slides using *Crithidia luciliae* as the substrate to increase the specificity and sensitivity of the analyzed methods. Serum complement levels were measured by nephelometry. Tests for anti-phospholipid antibodies (aPLA) included assessments of lupus anticoagulant, anti-cardiolipin antibodies, and anti- β_2 -glycoprotein I antibodies (both IgM and IgG classes). Laboratory tests were performed at a third-grade reference laboratory by a diagnostic analyst specializing in immunology.

Statistics analysis

Data analysis was conducted using STATISTICA Tibco 13.3 software (StatSoft Inc., Tulsa, OK, USA). Categorical variables were presented as frequencies and percentages. Comparisons between groups were performed using either the χ^2 test or Fisher's exact test, as appropriate. The Shapiro-Wilk test was employed to assess normality, indicating that all continuous variables were non-normally distributed. Consequently, these variables were reported as medians with Q1–Q3 ranges and analyzed using the Mann-Whitney test. Odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated based on receiver operating characteristic curve analysis. Statistical significance was defined as a p-value of less than 0.05.

Bioethical standards

This study was approved by the Bioethics Committee of Jagiellonian University Medical College (approval number: 118.6120.21.2023, dated 15 June 2023), with all research activities conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.

Results

Demographic features

A summary of the demographic characteristics is provided in Table I. Early-onset SLE and Lo-SLE patients were similar in terms of sex, with a high predominance of females in both groups. As expected, the Lo-SLE patients were older, with older age at SLE onset and first symptoms, but with shorter SLE duration. Interestingly, a higher mortality rate was also documented in these patients (OR = 4.10, 95% CI: 2.02–8.33, $p < 0.001$). Table II presents detailed information on the causes of death among patients with SLE.

Lower frequency of central nervous system and kidney involvement and higher prevalence of interstitial lung disease in late-onset systemic lupus erythematosus patients

Table III summarizes the cumulative frequencies of systemic symptoms across the SLE study groups. Overall, in the Eo-SLE group, the most prevalent clinical manifestations included hematological (90.85%) and joint (88.87%) symptoms, as well as mucocutaneous manifestations (82.68%). On the other hand, the Lo-SLE group exhibited comparable predominant symptoms, with hematological (81.59%), joint (80.60%), and constitutional (74.63%) signs being the most frequent.

However, compared to the Eo-SLE group, the Lo-SLE cohort less frequently exhibited systemic clinical manifestations, including fever (OR = 0.50, 95% CI: 0.35–0.71, $p < 0.001$) and lymphadenopathy (OR = 0.42, 95% CI: 0.24–0.71, $p < 0.001$). In the Lo-SLE group, mucocutaneous manifestations were also less frequent, such as lupus malar rash (OR = 0.68, 95% CI: 0.49–0.95, $p = 0.023$),

Table II. Detailed characteristics of death causes in patients with early-onset and late-onset systemic lupus erythematosus

Characteristic	Deceased patients with Eo-SLE (n = 20)	Deceased patients with Lo-SLE (n = 19)	p
Malignancy [n (%)]	1 (5)	1 (5.26)	0.11
Infection [n (%)]	3 (15)	6 (31.58)	
SLE exacerbation [n (%)]	3 (15)	0 (0)	
SLE exacerbation and malignancy [n (%)]	1 (5)	0 (0)	
Others [n (%)]	4 (20)	1 (5.26)	
Unknown [n (%)]	8 (40)	11 (57.89)	

Categorical variables are presented as numbers with percentages.

Eo-SLE – early-onset systemic lupus erythematosus, Lo-SLE – late-onset systemic lupus erythematosus, SLE – systemic lupus erythematosus.

Table III. Cumulative frequencies of systemic involvement in patients with early-onset and late-onset systemic lupus erythematosus

Clinical manifestations	Patients with Eo-SLE (n = 710)	Patients with Lo-SLE (n = 201)	p
Constitutional symptoms [n (%)]	540 (76.06)	150 (74.63)	0.68
Fever	307 (44.62)	57 (28.64)	< 0.001
Fatigue/weakness	433 (62.94)	118 (59.6)	0.39
Myalgias	266 (38.66)	70 (35.35)	0.40
Weight loss	141 (20.55)	45 (22.61)	0.53
Lymphadenopathy	139 (20.17)	19 (9.6)	< 0.001
Mucocutaneous manifestations [n (%)]	587 (82.68)	142 (70.65)	< 0.001
Lupus malar rash	317 (45.22)	72 (36)	0.020
Discoid rash	63 (8.99)	13 (6.5)	0.26
Urticaria	63 (8.99)	7 (3.5)	0.01
Cutaneous vasculitis	45 (6.42)	9 (4.5)	0.31
Alopecia	200 (28.45)	28 (14)	< 0.001
Oral and/or nasal ulcers	115 (16.41)	22 (11)	0.06
Photosensitivity	233 (33.24)	69 (34.33)	0.77
Other skin changes ^a	474 (67.33)	115 (57.5)	0.010
Joint manifestations [n (%)]	631 (88.87)	162 (80.6)	0.002
Arthritis	438 (62.48)	91 (45.27)	< 0.001
Arthralgia	627 (88.81)	163 (81.1)	0.004
Serositis [n (%)]	166 (23.85)	42 (21)	0.40
Pleural effusion	112 (15.84)	35 (17.41)	0.59
Pericardial effusion	99 (14.22)	23 (11.5)	0.32
Pericarditis	30 (4.25)	4 (2)	0.14
Hematological manifestations [n (%)]	645 (90.85)	164 (81.59)	< 0.001
Leucopenia ^b	446 (64.64)	89 (45.64)	< 0.001
Lymphopenia ^c	499 (74.15)	128 (67.37)	0.06
Anemia ^d	486 (70.23)	124 (63.27)	0.06
Hemolytic anemia ^e	61 (19.61)	18 (16.51)	0.48
Thrombocytopenia ^f	220 (31.93)	56 (28.57)	0.37
Macrophage activation syndrome	7 (1)	1 (0.51)	0.51
Thrombotic thrombocytopenic purpura	2 (0.28)	0 (0)	0.45

Table III. Cont.

Clinical manifestations	Patients with Eo-SLE (n = 710)	Patients with Lo-SLE (n = 201)	p
Kidney involvement [n (%)]	294 (41.41)	49 (24.38)	< 0.001
24-hour urinary protein excretion > 0.5 g/day	249 (36.19)	37 (18.97)	< 0.001
24-hour urinary protein excretion > 3.5 g/day	126 (19.27)	17 (8.95)	< 0.001
Urinary casts	106 (17.29)	12 (6.42)	< 0.001
Erythrocyturia	182 (28.04)	34 (17.71)	0.004
Leucocyturia	212 (32.02)	37 (19.07)	< 0.001
Neurological signs [n (%)]	72 (10.21)	14 (7)	0.17
Central nervous system involvement	51 (7.23)	5 (2.5)	0.014
Peripheral nervous system involvement	33 (4.68)	9 (4.5)	0.91
Raynaud's phenomenon [n (%)]	192 (27.16)	27 (13.43)	< 0.001
Lung involvement [n (%)]	45 (6.48)	27 (13.5)	0.001
Interstitial lung disease	27 (3.84)	19 (9.45)	0.001
Diffuse alveolar hemorrhage	6 (0.85)	3 (1.49)	0.42
Pulmonary hypertension	18 (2.59)	8 (4)	0.30
Lupoid hepatitis [n (%)]	34 (4.81)	13 (6.47)	0.35

Categorical variables are presented as numbers with percentages, and continuous variables are presented as medians with Q1–Q3 ranges.

^aErythema, livedo racemosa, livedo reticularis.

^b< 4,000/ μ l or diagnosis based on medical history.

^c< 1,500/ μ l or diagnosis based on medical history.

^d \leq 12 g/dl in women, \leq 13.5 g/dl in men, or diagnosis based on medical history.

^eAnemia with positive direct Coombs test, anemia with decreased haptoglobin level, or diagnosis based on medical history.

^f< 100,000/ μ l or diagnosis based on medical history.

urticaria (OR = 0.37, 95% CI: 0.14–0.82, p = 0.010), RP (OR = 0.42, 95% CI: 0.26–0.65, p < 0.001), and alopecia (OR = 0.41, 95% CI: 0.26–0.64, p < 0.001). Likewise, arthritis and arthralgias were less common in these patients (OR = 0.50, 95% CI: 0.36–0.69, p < 0.001 and OR = 0.54, 95% CI: 0.35–0.85, p = 0.006, respectively), similar to all hematological manifestations, e.g., leucopenia (OR = 0.46, 95% CI: 0.33–0.64, p < 0.001).

Additionally, the Lo-SLE group in comparison to Eo-SLE was characterized by less frequent kidney involvement, defined by the presence of urinary casts (OR = 0.33, 95% CI: 0.16–0.62, p < 0.001), 24-hour urinary protein excretion > 0.5 g/day (OR = 0.41, 95% CI: 0.27–0.62, p < 0.001), 24-hour urinary protein excretion > 3.5 g/day (OR = 0.41, 95% CI: 0.23–0.71, p < 0.001), leucocyturia (OR = 0.50, 95% CI: 0.33–0.75, p < 0.001), and erythrocyturia (OR = 0.55, 95% CI: 0.36–0.84, p = 0.004). Table IV presents the results of kidney biopsies in SLE patients with lupus nephritis, classified according to the International Society of Nephrology/ Renal Pathology Society criteria.

On the other hand, the only more frequent Lo-SLE clinical manifestation was interstitial lung disease (OR = 2.61, 95% CI: 1.34–5.00, p = 0.003). Finally, patients with Lo-SLE exhibited a lower incidence of central ner-

vous system involvement (OR = 0.33, 95% CI: 0.10–0.84, p = 0.012).

Higher frequency of medical comorbidities in patients with late-onset systemic lupus erythematosus

As expected, the Lo-SLE patients more frequently suffered from medical comorbidities than Eo-SLE patients (Table V). In the former group, particularly common were those predisposing or related to cardiovascular events, such as arterial hypertension (OR = 3.49, 95% CI: 2.44–5.05, p < 0.001), diabetes mellitus (OR = 2.67, 95% CI: 1.63–4.32, p < 0.001), hypercholesterolemia (OR = 1.52, 95% CI: 1.09–2.10, p = 0.010), atrial fibrillation (OR = 3.55, 95% CI: 1.68–7.45, p < 0.001), peripheral artery obliterans disease (OR = 3.33, 95% CI: 1.72–6.40, p < 0.001), myocardial infarction (OR = 3.59, 95% CI: 1.94–6.6, p < 0.001), and heart failure (OR = 2.65, 95% CI: 1.36–5.07, p = 0.003).

In Lo-SLE patients, malignancy and monoclonal gammopathy of undetermined significance occurred more often (OR = 2.77, 95% CI: 1.71–4.45, p < 0.001, and OR = 7.36, 95% CI: 2.26–27.77, p < 0.001, respectively).

Table IV. Summary of lupus nephritis classes according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria in early-onset and late-onset systemic lupus erythematosus patients with lupus nephritis

Class of lupus nephritis	Patients with Eo-SLE and kidney biopsy (n = 135)	Patients with Lo-SLE and kidney biopsy (n = 15)	p
Class I [n (%)]	2 (1.48)	0 (0)	0.52
Class II [n (%)]	25 (18.52)	3 (20)	
Class III [n (%)]	18 (13.33)	4 (26.67)	
Class IV [n (%)]	68 (50.37)	5 (33.33)	
Class V [n (%)]	17 (12.59)	3 (20)	
Class VI [n (%)]	5 (3.70)	0 (0)	

Categorical variables are presented as numbers with percentages.

Eo-SLE – early-onset systemic lupus erythematosus, Lo-SLE – late-onset systemic lupus erythematosus.

Table V. Cumulative frequencies of comorbidities in patients with early-onset and late-onset systemic lupus erythematosus

Characteristic	Patients with Eo-SLE (n = 710)	Patients with Lo-SLE (n = 201)	p
Hypothyroidism [n (%)]	169 (23.87)	50 (24.88)	0.77
Hyperthyroidism [n (%)]	35 (4.94)	8 (3.98)	0.57
Arterial hypertension [n (%)]	320 (45.07)	149 (74.13)	< 0.001
Diabetes mellitus [n (%)]	52 (7.32)	35 (17.41)	< 0.001
Heart failure ^a [n (%)]	27 (3.81)	19 (9.5)	0.001
Hypercholesterolemia ^b [n (%)]	311 (43.87)	109 (54.23)	0.009
Atrial fibrillation [n (%)]	18 (2.54)	17 (8.46)	< 0.001
Peripheral artery obliterans disease [n (%)]	24 (3.38)	21 (10.45)	< 0.001
End-stage kidney disease [n (%)]	20 (2.83)	5 (2.49)	0.80
MGUS [n (%)]	5 (0.7)	10 (4.98)	< 0.001
Malignancy [n (%)]	54 (7.61)	37 (18.59)	< 0.001
Arterial thrombotic episode [n (%)]	59 (8.32)	42 (20.9)	< 0.001
Stroke	48 (6.76)	21 (10.45)	0.08
Transient ischemic attack	10 (1.41)	4 (2)	0.55
Myocardial infarct	27 (3.8)	25 (12.44)	< 0.001
Other arterial thrombotic episodes	14 (1.97)	6 (2.99)	0.39
Venous thrombotic episode [n (%)]	122 (17.26)	37 (18.41)	0.70
Deep venous thrombosis	107 (15.09)	29 (14.43)	0.82
Pulmonary embolism	26 (3.67)	11 (5.47)	0.25
Deep venous thrombosis and pulmonary embolism	16 (2.26)	5 (2.49)	0.85
Other venous thrombotic episodes	9 (1.27)	6 (2.99)	0.09
Miscarriage	85 (16.04)	17 (12.69)	0.34

Categorical variables are presented as numbers with percentages, and continuous variables are presented as medians with Q1–Q3 ranges.

^aSymptoms of heart failure, left ventricular ejection fraction of $\leq 40\%$, or diagnosis based on medical history.

^bLow-density lipoprotein level of > 3 mmol/l, pharmacotherapy with statin, or diagnosis based on medical history.

MGUS – monoclonal gammopathy of undetermined significance.

Distinct antibody profiles in patients with late-onset and early-onset systemic lupus erythematosus

All patients exhibited positive ANA results as determined by the indirect immunofluorescence (Table VI). In patients with Lo-SLE, we observed a lower prevalence of SLE-specific antibodies, including anti-dsDNA (OR = 0.62, 95% CI: 0.43–0.90, $p = 0.009$), anti-nucleosome (OR = 0.50, 95% CI: 0.33–0.75, $p < 0.001$), and anti-histone (OR = 0.48, 95% CI: 0.30–0.75, $p < 0.001$) antibodies. Regarding other autoantibodies, anti-SSB antibodies were more frequently detected (OR = 1.46, 95% CI: 1.01–2.09, $p = 0.040$), whereas anti-RNP antibodies were less prevalent (OR = 0.40, 95% CI: 0.23–0.67, $p < 0.001$). Concerning APS, lupus anticoagulant and anti-cardiolipin antibodies in the IgG class were less frequently present in Lo-SLE patients (OR = 0.51, 95% CI: 0.32–0.79, $p = 0.002$). Importantly, in the Eo-SLE group, thrombotic events were significantly more frequent

among aPLA-positive patients compared to aPLA-negative individuals. Arterial thromboses occurred in 13.68% ($n = 32/234$) vs. 4.44% ($n = 4/90$), $p = 0.010$; venous thromboses in 27.20% ($n = 96/353$) vs. 12.03% ($n = 19/158$), $p < 0.001$; and any thrombosis in 35.13% ($n = 124/353$) vs. 17.09% ($n = 27/158$), $p < 0.001$. In the Lo-SLE group, rates of thrombotic events did not differ significantly between aPLA-positive and aPLA-negative patients: arterial thromboses in 26.32% ($n = 10/38$) vs. 15.00% ($n = 3/20$), $p = 0.51$; venous thromboses in 33.85% ($n = 22/65$) vs. 23.68% ($n = 9/38$), $p = 0.27$; and any thrombosis in 47.69% ($n = 31/65$) vs. 34.21% ($n = 13/38$), $p = 0.18$.

Interestingly, among patients with Eo-SLE but not Lo-SLE, the presence of anti-RNP antibodies was significantly associated with higher frequency of constitutional symptoms (OR = 1.87, 95% CI: 1.16–3.01) including fever, fatigue/weakness; serositis (OR = 1.97, 95% CI: 1.32–2.93) such as pleural effusion, pericardial effusion and pericarditis; hematological manifestations (OR = 4.27, 95% CI:

Table VI. Autoantibody profile in patients with early-onset and late-onset systemic lupus erythematosus

Parameter (number of patients with analyzed parameter)	Patients with Eo-SLE ($n = 710$)	Patients with Lo-SLE ($n = 201$)	p
ANA – IIF assay, titer ^a	1 : 5,120 (1 : 2,560–1 : 20,480)	1 : 5,120 (1 : 2,560–1 : 20,480)	0.50
Anti-SjDA antibodies ^b [n (%)]	397 (59.25)	107 (58.79)	0.91
Anti-SjDB antibodies ^b [n (%)]	185 (27.61)	65 (35.71)	0.030
Anti-histone antibodies ^b [n (%)]	189 (28.21)	29 (15.93)	< 0.001
Anti-nucleosome antibodies ^b [n (%)]	231 (34.48)	38 (20.88)	< 0.001
Anti-Smith antibodies ^b [n (%)]	82 (12.28)	16 (8.84)	0.20
Anti-RNP antibodies ^b [n (%)]	158 (23.62)	20 (11.05)	< 0.001
Anti-dsDNA antibodies ^b [n (%)]	250 (37.37)	59 (32.96)	0.28
Anti-dsDNA antibodies ^c [n (%)]	443 (69.76)	99 (58.93)	0.008
Anti-dsDNA antibodies (positive in any of the analyzed methods) [n (%)]	481 (74.69)	115 (68.86)	0.13
Lupus anticoagulant [n (%)]	158 (30.56)	22 (20)	0.030
Anti-cardiolipin antibodies IgG and/or IgM [n (%)]	319 (56.16)	60 (48.78)	0.14
Anti-cardiolipin antibodies IgG	243 (42.93)	34 (27.64)	0.002
Anti-cardiolipin antibodies IgM	217 (38.48)	45 (36.59)	0.70
Anti- β_2 glycoprotein I IgG and/or IgM [n (%)]	112 (24.78)	27 (28.72)	0.42
Anti- β_2 glycoprotein I IgG	77 (17.11)	15 (16.13)	0.82
Anti- β_2 glycoprotein I IgM	74 (16.48)	21 (22.34)	0.17

Categorical variables are presented as numbers with percentages, and continuous variables are presented as medians with Q1–Q3 ranges.

^aPositive in all patients.

^bImmunoblotting assay.

^c*Crithidia luciliae* immunofluorescence test.

ANA – antinuclear antibodies, dsDNA – double-stranded DNA, Ig – immunoglobulin, IIF – indirect immunofluorescence, RNP – ribonucleoprotein, SjDA – Sjögren's disease-related antigen A, SjDB – Sjögren's syndrome-related antigen B.

Table VII. Treatment patterns in patients with early-onset and late-onset systemic lupus erythematosus

Treatment	Patients with Eo-SLE (n = 710)	Patients with Lo-SLE (n = 201)	p
Glucocorticosteroids (oral/intravenous) [n (%)]	673 (95.19)	182 (91.46)	0.040
Chloroquine or hydroxychloroquine [n (%)]	559 (79.63)	128 (63.68)	< 0.001
Azathioprine [n (%)]	307 (43.86)	39 (19.5)	< 0.001
Cyclosporine [n (%)]	64 (9.17)	7 (3.5)	0.010
Belimumab [n (%)]	35 (5.04)	2 (1)	0.010
Mycophenolate mofetil [n (%)]	233 (33.43)	36 (18)	< 0.001
Cyclophosphamide [n (%)]	218 (31.19)	33 (16.5)	< 0.001
Rituximab [n (%)]	26 (3.74)	3 (1.5)	0.11
Immunoglobulins [n (%)]	26 (3.74)	2 (1)	0.05
Plasmapheresis [n (%)]	23 (3.31)	5 (2.5)	0.56
Anifrolumab [n (%)]	7 (1.01)	1 (0.5)	0.50

Categorical variables are presented as numbers with percentages. Statistically significant differences are bolded. Eo-SLE – early-onset systemic lupus erythematosus, Lo-SLE – late-onset systemic lupus erythematosus.

1.52–12.00), including leucopenia, lymphopenia, hemolytic anemia, and thrombocytopenia; and RP (OR = 3.65, 95% CI: 2.50–5.33).

Patients with late-onset systemic lupus erythematosus were less frequently treated with immunosuppressive medications

Next, we analyzed the various approaches to immunosuppressive therapy (Table VII). Glucocorticosteroids (GCs) were the most commonly administered treatment for both the Eo-SLE and Lo-SLE groups. However, Lo-SLE received this medication slightly less frequently (95.19% and 91.46%, respectively, $p = 0.040$). Likewise, Lo-SLE patients were less frequently prescribed certain immunosuppressive regimens, including belimumab (OR = 0.19, 95% CI: 0.02–0.75, $p = 0.008$), azathioprine (OR = 0.31, 95% CI: 0.21–0.46, $p < 0.001$), cyclosporine (OR = 0.36, 95% CI: 0.14–0.80, $p = 0.007$), mycophenolate mofetil (OR = 0.44, 95% CI: 0.29–0.66, $p < 0.001$), cyclophosphamide (OR = 0.44, 95% CI: 0.28–0.66, $p < 0.001$), and chloroquine or hydroxychloroquine (OR = 0.45, 95% CI: 0.32–0.64, $p < 0.001$).

Discussion

The present study reveals clinical and laboratory characteristics of a large cohort of SLE patients from a single center, focusing on those diagnosed before the age of 50 compared to those diagnosed at 50 years or older. Our findings revealed that the age of onset significantly impacts the clinical presentation and pro-

gression of the disease. These distinctions offer valuable insights into overall prognosis, including the likelihood of organ-related complications and mortality. Our study describes one of the largest Polish cohorts of SLE patients in the literature, comparing various aspects of the disease based on the age of SLE onset.

In general, most SLE patients had early-onset disease, consistent with the current literature on this topic [5]. Late-onset SLE is used in the literature when the disease is diagnosed after the age of 50–65 years, although most studies use 50 years as the threshold [5, 6]. Interestingly, in our cohort of Eo-SLE and Lo-SLE patients, we noted a high prevalence of the female sex in both groups but with a slightly lower female-to-male ratio in the Lo-SLE group. According to the literature, female-to-male ratios in Eo-SLE and Lo-SLE differ, with lower values in Lo-SLE patients [5]. Interestingly, a Spanish multicenter registry cohort (RELESSER group) reported an almost two-fold lower female-to-male ratio in the Lo-SLE group [6]. Likewise, a study on a Polish cohort noted that the prevalence of SLE in males was higher in Lo-SLE compared to younger patients [9]. On the other hand, Aljoaani et al. [8] found similar percentages, similar to our study, of females in late-onset and younger-onset SLE groups (84.9% vs. 86.4%), potentially due to differences in inclusion criteria for the younger-onset group. These distinctions in sex ratios in SLE highlight the potential role of different underlying factors, such as genetic and hormonal influences, in the age-related onset of the disease.

In both groups, hematological and joint symptoms were the most common, which is consistent with previous studies on large SLE cohorts [6, 13]. However,

the Eo-SLE cohort exhibited a higher prevalence of a broader range of clinical manifestations, including general symptoms (fever, lymphadenopathy), hematological (leukopenia), skin manifestations (alopecia, urticaria, lupus malar rash), and kidney and central nervous system involvement. This observation aligns with a report published by Riveros Frutos et al. [6], who found that hematological, renal, neuropsychiatric, and skin changes were the most frequent in the Eo-SLE group. Also in line with those results are data presented by Bindroo et al. [14], with alopecia, RP, and lymphadenopathy reported more frequently in Eo-SLE than Lo-SLE. Next, a meta-analysis by Medlin et al. [15] demonstrated, in contrast to our results, that serositis and pleuritis can also be found more frequently in the Eo-SLE group. On the other hand, interstitial lung disease was more frequently observed in Lo-SLE in our data and also in other studies [14, 16]. These findings suggest the possibility of overlap syndromes, such as SLE/SjD, which may contribute to lung involvement in these patients [17]. The same association is further supported by the higher prevalence of anti-SSB antibodies, characteristic of SjD, in Lo-SLE, which was published in the literature [17] and also documented in our data. Furthermore, Catoggio et al. [16] found sicca symptoms more frequent in older SLE patients, which also suggests suspicion of SjD. Unfortunately, data on sicca symptoms or overlapping autoimmune diseases such as SjD were not available for our cohort.

In our data, neuropsychiatric SLE was also less frequent in Lo-SLE than in Eo-SLE patients. This observation is in line with previously published data by Pamuk et al. [18], where symptoms of neuropsychiatric SLE were 1.41-fold more common in younger patients. In contrast, Jeleniewicz et al. [9] did not find differences in the frequency of neuropsychiatric SLE symptoms regarding patient age, likely attributable to the limited sample size of the studied groups.

We also found that Lo-SLE was characterized by a higher prevalence of medical comorbidities and malignancies, which may be linked to the age-related nature of these conditions and has been reported previously by other authors [6, 19, 20]. Moreover, similarly to our findings, specific comorbidities, such as arterial hypertension or dyslipidemia, may also influence the outcome of SLE [6]. Interestingly and consistent with previous data, arterial thromboembolic episodes were observed more frequently in Lo-SLE, specifically myocardial infarction [21]. Additionally, in our stratified analysis, thrombotic events were significantly more frequent in aPLA-positive patients with Eo-SLE, supporting the interpretation of these events as clinical manifestations of APS. In contrast, in Lo-SLE, thromboses occurred at similar rates regardless of aPLA status (positive vs. negative), suggesting they

may reflect comorbidities or age-related vascular risk rather than APS.

In our data, the Lo-SLE group was characterized by a lower frequency of positive results for lupus anticoagulant and anti-cardiolipin antibodies in the IgG class. Moreover, SLE-characteristic ANA types were more common in Eo-SLE. This observation largely agrees with data presented in the review by Piga et al. [7], who highlighted a lower prevalence of anti-dsDNA, anti-nucleosome, anti-Sm, anti-RNP antibodies, and lupus anticoagulant positivity in Lo-SLE. Furthermore, this serological profile could influence or reflect the disease course, including treatment mode [7]. We observed a similar high prevalence of anti-dsDNA antibodies in Eo-SLE and Lo-SLE groups as measured by the *Crithidia luciliae* assay or immunoblotting. However, when these antibodies were assessed by the *Crithidia luciliae* assay characterized by higher sensitivity and specificity [22], their prevalence in patients from the Eo-SLE group increased. In contrast to our findings, Padovan et al. [23] reported a higher prevalence of anti-dsDNA antibodies in Lo-SLE. However, similar to our results, anti-SSB, and in some cases, anti-SSA antibodies, were more frequently present in Lo-SLE [7]. Another interesting finding of our study concerns the association between anti-RNP antibodies and clinical signs of Eo-SLE but not Lo-SLE. In the former group only, the presence of anti-RNP antibodies was related to the higher frequency of constitutional symptoms, serositis, hematological abnormalities, and RP. This observation aligns with a report by Riveros Frutos et al. [6], in which anti-RNP antibodies were significantly more common in patients with Eo-SLE, particularly in those with systemic symptoms such as fever, hematologic manifestations, serositis, and RP. According to them, anti-RNP antibodies were less common in Lo-SLE patients and were not associated with any specific clinical features [6].

Regarding therapy mode, both subgroups were treated the most frequently with GCs, chloroquine, or hydroxychloroquine, which aligns with EULAR recommendations from 2019 [24]. Furthermore, considering that most Eo-SLE patients presented with more signs of the disease, including kidney involvement and neuropsychiatric manifestations, they required frequent immunosuppressive drugs [6]. Adverse effects of that aggressive treatment, such as the increased risk of infections and organ toxicity, necessitate careful use in older patients [25]. Likewise, drug interactions underscore the importance of individualized pharmacotherapy in optimizing safety and efficacy in Lo-SLE [26].

Finally, we observed a higher mortality rate in Lo-SLE compared to Eo-SLE, which mirrors other data on SLE [6, 27]. In the study by Riveros Frutos et al. [6], mortality

was higher in the Lo-SLE group when compared to Eo-SLE patients (14.3% vs. 4.7%, $p < 0.001$). A study by Viveiros et al. [27] documented that very late-onset SLE patients (≥ 60 years at the time of diagnosis) had the lowest survival rate compared to younger SLE groups, including those with SLE diagnosis between 50 and 59 years.

Study limitations

The retrospective design of this study introduces potential biases in data collection and patient selection, which could affect the reliability of the findings. Additionally, the single-center nature of the study may restrict the applicability of the results to a broader population. Essential lifestyle factors, such as smoking, alcohol consumption, physical activity, and dietary habits, were not accounted for in the database. Furthermore, key laboratory and clinical data, including inflammatory markers, lupus disease activity indices, and sicca symptoms, were unavailable for this cohort. The higher clinical incidence of thrombosis in Lo-SLE, despite lower frequencies of antiphospholipid antibodies, suggests a potential non-immune-mediated etiology or low test sensitivity. Therefore, these results should be interpreted cautiously. Moreover, due to the retrospective nature of the study, the use of disease activity indices, such as SLEDAI, was not feasible. This limitation stemmed from the absence of specific data required for score calculation at potential control time points and the variability in patient follow-up duration. A further limitation of the study is the lack of analysis regarding the impact of specific treatments on disease outcomes. Finally, some observed associations may be coincidental and not indicate causal relationships.

Conclusions

Late-onset SLE patients exhibited distinct clinical characteristics compared to Eo-SLE, with fewer disease-related manifestations, suggesting that these individuals may require less intensive immunosuppressive therapy. Notably, interstitial lung disease was more prevalent among older patients, highlighting a need for closer monitoring of pulmonary complications in this group. Furthermore, Lo-SLE was associated with a higher burden of medical comorbidities, malignancies, and arterial thromboembolic events, emphasizing the importance of a comprehensive approach to managing these patients. The ANA profile in Lo-SLE also differed, showing a reduced variety and frequency of autoantibodies, apart from anti-SSB antibodies, which may indicate a greater likelihood of overlap with SjD. Our findings underscore the need for further research to validate this potential association and optimize care for Lo-SLE patients.

Disclosures

Conflict of interest: The authors declare no conflict of interest.

Funding: This work was supported by a Research Grant of Jagiellonian University Medical College, no. N41/DBS/000936 (to J.K.-W.).

Ethics approval: This study was approved by the Bioethics Committee of Jagiellonian University Medical College (approval number: 118.6120.21.2023, dated 15 June 2023).

Data availability: The data that support the findings of this study are available on request from the corresponding author (J.K.-W.).

References

- Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. *Lancet* 2024; 403: 2326–2338, DOI: 10.1016/S0140-6736(24)-00398-2.
- Lisnevskaja L, Murphy G, Isenberg D. Systemic lupus erythematosus. *Lancet* 2014; 384: 1878–1888, DOI: 10.1016/S0140-6736(14)60128-8.
- Wach A, Korkosz M, Okoń K, Kosałka-Węgiel J. A case of systemic lupus erythematosus with antineutrophil cytoplasmic antibodies positive skin vasculitis and concomitant combined thrombophilia. *Pol Arch Intern Med* 2024; 134: 16810, DOI: 10.20452/pamw.16810.
- Celińska-Löwenhoff M, Musiał J. Late-onset systemic lupus erythematosus: clinical manifestations, course, and prognosis. *Pol Arch Intern Med* 2015; 125: 497–499.
- Mruthunjaya P, Ahmed S, Botabekova A, et al. Late-onset Systemic Lupus Erythematosus. *Rheumatol Int* 2025; 45: 29, DOI: 10.1007/s00296-024-05784-1.
- Riveros Frutos A, Holgado S, Sanvisens Bergé A, et al. Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). *Rheumatology (Oxford)* 2021; 60: 1793–1803, DOI: 10.1093/rheumatology/keaa477.
- Piga M, Tselios K, Viveiros L, et al. Clinical patterns of disease: From early systemic lupus erythematosus to late-onset disease. *Best Pract Res Clin Rheumatol* 2023; 37: 101938, DOI: 10.1016/j.berh.2024.101938.
- Aljohani R, Gladman DD, Su J, Urowitz MB. Disease evolution in late-onset and early-onset systemic lupus erythematosus. *Lupus* 2017; 26: 1190–1196, DOI: 10.1177/0961203317696593.
- Jeleniewicz R, Suszek D, Majdan M. Clinical picture of late-onset systemic lupus erythematosus in a group of Polish patients. *Pol Arch Intern Med* 2015; 125: 538–544, DOI: 10.20452/pamw.2963.
- Aringer M. EULAR/ACR classification criteria for SLE. *Semin Arthritis Rheum* 2019; 49 (Suppl 3): S14–S17, DOI: 10.1016/j.semarthrit.2019.09.009.
- Kosałka-Węgiel J, Dziedzic R, Siwiec-Koźlik A, et al. Clinical and laboratory characteristics of early-onset and delayed-onset lupus nephritis patients: a single-center retrospective study. *Rheumatol Int* 2024; 44: 1283–1294, DOI: 10.1007/s00296-024-05579-4.

12. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum* 1999; 42: 599–608, DOI: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
13. Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic Lupus Erythematosus in Northwestern Spain: A 20-Year Epidemiologic Study. *Medicine (Baltimore)* 2011; 90: 350–358, DOI: 10.1097/MD.0b013e31822edf7f.
14. Bindroo MA, Majid N, Ekbote G, et al. Late Onset Systemic Lupus Erythematosus – Clinical and Autoantibody Profile and its Comparison with Young Onset Systemic Lupus Erythematosus. *Mediterr J Rheumatol* 2023; 34: 454–459, DOI: 10.31138/mjr.290723.los.
15. Medlin JL, Hansen KE, McCoy SS, Bartels CM. Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis. *Semin Arthritis Rheum* 2018; 48: 198–204, DOI: 10.1016/j.semarthrit.2018.01.010.
16. Catoggio LJ, Soriano ER, Imamura PM, et al. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup? *Lupus* 2015; 24: 788–795, DOI: 10.1177/0961203314563134.
17. Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren’s syndrome: a clinical review. *Clin Exp Rheumatol* 2020; 38 Suppl 126: 291–300.
18. Pamuk ON, Raza AA, Hasni S. Neuropsychiatric lupus in late- and early-onset systemic lupus erythematosus patients: a systematic review and meta-analysis. *Rheumatology* 2024; 63: 8–15, DOI: 10.1093/rheumatology/kead297.
19. Maddison P, Farewell V, Isenberg D, et al.; Systemic Lupus International Collaborating Clinics. The rate and pattern of organ damage in late onset systemic lupus erythematosus. *J Rheumatol* 2002; 29: 913–917.
20. Kosatka-Węgiel J, Pacholczak-Madej R, Dziedzic R, et al. Malignancy in systemic lupus erythematosus: relation to disease characteristics in 92 patients – a single center retrospective study. *Rheumatol Int* 2024; 44: 1701–1713, DOI: 10.1007/s00296-024-05623-3.
21. Dong Z, Hou L, Luo W, et al. Myocardial infarction drives trained immunity of monocytes, accelerating atherosclerosis. *Eur Heart J* 2024; 45: 669–684, DOI: 10.1093/eurheartj/ehad787.
22. Mahir L, Ezzahra Hsai F, Drissi Bourhanbour A, El Bakkouri J. Performance evaluation of immunoblot for the detection of anti-DNA antibodies compared to indirect immunofluorescence on *Crithidia luciliae*. *J Hum Virol Retrovirol* 2023; 10: 30–32.
23. Padovan M, Govoni M, Castellino G, et al. Late onset systemic lupus erythematosus: no substantial differences using different cut-off ages. *Rheumatol Int* 2007; 27: 735–741, DOI: 10.1007/s00296-006-0284-3.
24. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019; 78: 736–745, DOI: 10.1136/annrheumdis-2019-215089.
25. Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Immunosuppressants. *Psychosomatics* 2004; 45: 354–360, DOI: 10.1176/appi.psy.45.4.354.
26. Rodrigues MCS, Oliveira CD. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. *Rev Lat Am Enfermagem* 2016; 24: e2800, DOI: 10.1590/1518-8345.1316.2800.
27. Viveiros L, Neves A, Gouveia T, Isenberg DA. A large cohort comparison of very late-onset systemic lupus erythematosus with younger-onset patients. *Clin Exp Rheumatol* 2024; 42: 1480–1486, DOI: 10.55563/clinexp/rheumatol/jgsyos.